PART VI- Summary of the risk management plan

Summary of risk management plan (RMP) for Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett (Sertraline hydrochloride)

This is a summary of risk management plan for Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett. The RMP details important risks of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett, and how more information will be obtained about Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett, risks and uncertainties (missing information).

Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett´s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett should be used.

Important new concerns or changes to the current ones will be included in updates of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett's RMP.

I. The medicine and what it is used for

Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett is authorised for the treatment of:

- Major depressive disorder and prevention of recurrence of major depressive episodes
- Panic disorder, with or without agoraphobia
- Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years
- Social anxiety disorder
- Post traumatic stress disorder (PTSD)

It contains Sertraline hydrochloride as active substance, and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett, together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risk and missing information	
Important identified risks	• Serotonin syndrome • Suicidality
Important potential risks	• Diabetes mellitus • Use in pregnancy • Abnormal bleeding/haemorrhage
Missing information	• Use in paediatric patients, especially under age of 6 years

II.B Summary of important risks

The safety information in the proposed product information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Sertraline Medical Valley 25, 50, 100, 150 and 200 mg Filmdragerad tablett.